Release Date: July 30, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Trinet Group Inc TNET reported a 36% year-over-year improvement in overall customer attrition, driven by a 58% decrease in health fee pricing-related attrition and a 47% decrease in service-related attrition.
- The company's insurance cost ratio (ICR) improved to 86% in Q2, returning to its targeted range, and full-year ICR guidance was lowered to 88.5%-89.5%.
- Trinet Group Inc (TNET) is seeing strong early results from its AI-powered 'TriNet Assistant', which handles 50% of customer chat sessions, improving service efficiency and customer satisfaction.
- Sales momentum is returning with sequential improvement through Q2, supported by a 7% year-over-year increase in senior sales reps and a 54% year-over-year increase in broker-driven RFPs.
- The company raised its full-year 2026 adjusted EBITDA margin guidance to 8.5%-9% and adjusted EPS guidance to $4.50-$5.10, reflecting improved earnings performance.
- The Ascend sales training program is scaling, with over 100 new reps hired, and the company expects to end 2025 with approximately 20% more sales consultants than the prior year.
- The integration of the Cocoon leave-of-absence solution is on track, with the first customer cohort migrated and plans to onboard new PEO customers by January.
- Trinet Group Inc (TNET) generated $67 million in free cash flow in Q2, up 18% year-over-year, and returned $31 million to shareholders via buybacks and dividends.
Negative Points
- Total revenues declined 5% year-over-year to $1.2 billion, driven by a 12% decrease in total worksite employees (WSEs) and an 11% drop in co-employed WSEs.
- Professional services revenue fell 8% year-over-year, impacted by lower co-employed WSE counts, though it outperformed internal forecasts.
- Interest revenue dropped 33% year-over-year to $12 million, in line with expectations, due to reduced cash balances for certain tax credits.
- Health cost trends remain persistently high in the high single-digits, and the company expects normal ICR seasonality in the second half, which could pressure margins.
- Sales were flat year-over-year in Q2, with challenges persisting from March into April before momentum returned later in the quarter.
- The company experienced a contraction in its total sales force during the second half of 2025 and first half of 2026 due to a slowdown in traditional hiring while building the Ascend program.
- Customer hiring (CIE) did not accelerate in Q2, remaining consistent with last year's levels and in line with forecasts, indicating no near-term boost from client growth.
- The one-time benefit from recovered insurance administrative costs contributed to ICR improvement but is not expected to recur, and the company remains cautious on future pharma cost inflation.
Q & A Highlights
Here are the key highlights from the TriNet Group Inc (TNET) Q2 2026 earnings call.Q: What drives the confidence in returning to sales growth in the second half of 2026, given that Q2 sales were flat year-over-year?
A: (Mike Simonds, President and CEO) The confidence comes from several factors: sequential month-over-month improvement in sales momentum through Q2, which has continued into July; the total sales rep headcount is beginning to grow again; and the broker channel is showing strong momentum, with broker-driven RFPs up over 50% year-over-year. These investments in the Ascend program, retaining senior reps, and the broker channel give us confidence that full-year sales growth remains our target.
Q: Why doesn't the updated ICR guidance for the second half of 2026 suggest year-over-year improvement, despite the repricing efforts?
A: (Mala Murthy, CFO) The second-half ICR guidance factors in several elements. First, the year-to-date outperformance includes a one-time benefit and prior period development favorability. Second, while medical trends are stable, they remain persistently high in the high single-digits. Third, historical experience suggests potential lumpiness in claims in the second half. Finally, we expect normal second-half seasonality in ICR due to utilization patterns, deductibles being met, and pooling limit resets.
Q: What is resonating most with brokers and leading to the significant increase in RFPs?
A: (Mike Simonds, President and CEO) The success is driven by a focus on the fundamentals: putting the right local talent matched with the right broker producers, redesigning processes to give brokers "trust advisor" access and include them in renewal discussions, and dedicating client service personnel to the broker's block of business. It's about showing up as a true partner throughout the entire lifecycle, from prospecting to renewing.
Q: When should we expect WSE growth to turn positive, and where are clients going when they leave?
A: (Mike Simonds, President and CEO) The next mile marker is revenue growth, driven by improved retention slowing the WSE decline and pricing actions outpacing that decline. Following that, the sum total of growth investments in distribution, benefits, and service will turn the corner on WSE growth, though we are not pinpointing the exact timing. When clients leave due to healthcare pricing, they often go to an open market solution. When they leave for service reasons, we may lose to another competitor.
Q: How much of the insurance profitability improvement was due to timing versus a more sustainable core trend?
A: (Mala Murthy, CFO) The favorability is not characterized as timing. The year-over-year improvement was driven by two factors: a one-time benefit (about half the improvement) and prior year development favorability. The favorable emergence in prior year development is consistent with a stabilization in healthcare cost trends, which, while still high in the high single-digits, is a positive sign.
Q: How are you retaining high-performing sales reps for longer, and what metrics will define a successful fall selling season?
A: (Mike Simonds, President and CEO) Retention is driven by making it a focus, investing in frontline and regional management to build a stronger culture, and providing better tools and support to remove friction from the sales process. The new Ascend program also assigns junior reps to senior reps, providing administrative support. Success in the second half will be defined by strong year-over-year sales growth, continued acceleration in the broker channel, and growth in the direct channel.
Q: How are you thinking about the broker channel's influence on revenue trajectory, and what is the profitability of a new client versus an existing one?
A: (Mike Simonds, President and CEO) The broker channel currently represents about a third of new business, and that is growing, though direct sales will remain more than half. Profitability builds with tenure due to the cost of acquisition and, for a risk-taking PEO, a better understanding of the client's risk profile after two annual renewal cycles. This underscores why retention is critical for both volume growth and margin expansion.
Q: How are you leveraging AI within the organization, both from a revenue and expense perspective?
A: (Mike Simonds, President and CEO) AI is being used in several ways. A "customer health score" uses AI to monitor client interactions to predict NPS and retention, enabling proactive client management. AI is also used to select the right healthcare bundle for clients and powers the TriNet Assistant, which handles 50% of customer chat sessions. (Mala Murthy, CFO) AI tools are also being given to salespeople to improve prospecting and win rates.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
